Acceleron Pharma commences Stage 2 clinical trial of ACE-031 protein therapeutic in DMD patients Acceleron Pharma, Inc here ., a biopharmaceutical business developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Stage 2 medical trial with ACE-031 in sufferers with Duchenne Muscular Dystrophy , a fatal neuromuscular disease. ACE-031 can be an investigational protein therapeutic that builds muscle mass and increases strength by inhibiting signaling of a cell surface receptor known as the activin receptor type IIB .D., Chief Medical Officer at Acceleron.
Acadia proposes $150M in senior unsecured notes due 2021 Acadia Healthcare Organization, Inc. today announced that it’s proposing to issue $150 million in senior unsecured notes due 2021 in an exclusive offering that’s exempt from the sign up requirements of the Securities Work of 1933, as amended . The ongoing company intends to utilize the net arises from the providing for general corporate purposes, which may consist of acquisitions. The Notes are to be offered and then qualified institutional purchasers in reliance on Rule 144A beneath the Securities Take action and beyond your United States and then non-U.S. Persons pursuant to Regulation S.